Perrigo Co. (PRGO) said Tuesday that it has received U.S. Food and Drug Administration approval for its New Drug Application for testosterone gel 1%.
Perrigo's NDA included a bioequivalence study that compared its product to AbbVie's AndroGel 1%.
AndroGel 1% (testosterone gel 1%) is indicated to treat adult males who have low or no testosterone. Annual sales were about $705 million annually, as measured by Symphony Health.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.